|Articles|July 1, 2006
- Special Issues-07-01-2006
- Volume 0
- Issue 0
The Sands of Time Cannot be Stilled
The FDA has been implementing several changes in the way it does business, for example, relying on third-party inspections, academia, and industry in many new ways. The implementation of process analytical technology is among these changes.
Advertisement
Articles in this issue
about 20 years ago
Analytical Instrument Qualificationabout 20 years ago
GMP and Phase I Clinical Trials: Streamlining the Critical Path?about 20 years ago
Team Effortabout 20 years ago
Rated PG: Pharmaceutical Guidance Suggestedabout 20 years ago
European Clinical Trial Regulations Undergo a Slow Revolutionabout 20 years ago
Moving Biotech Products from CBER to CDER: A Work in Progressabout 20 years ago
FDA Video Interview Conducted by Jill Wechsler, Washington Bureau Chiefabout 20 years ago
New Climateabout 20 years ago
2006: A Regulatory OdysseyAdvertisement
Advertisement
Advertisement